XOMA (NASDAQ:XOMA) Raised to Hold at StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

Separately, HC Wainwright lowered their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd.

XOMA Stock Performance

Shares of XOMA stock opened at $27.10 on Tuesday. The company has a 50 day moving average of $26.81 and a 200-day moving average of $27.96. XOMA has a 1-year low of $19.50 and a 1-year high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a market cap of $319.24 million, a PE ratio of -7.79 and a beta of 0.90.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On XOMA

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its position in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. New York State Common Retirement Fund increased its position in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA during the fourth quarter worth $206,000. Rhumbline Advisers increased its position in shares of XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after buying an additional 1,699 shares during the period. Finally, Barclays PLC increased its position in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.